Valneva (VALN) Competitors

Sarepta Therapeutics (NASDAQ:SRPT) and Valneva (NASDAQ:VALN) are both medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their community ranking, earnings, profitability, analyst recommendations, valuation, institutional ownership, media sentiment, dividends and risk.

Does the MarketBeat Community prefer SRPT or VALN?

Sarepta Therapeutics received 1446 more outperform votes than Valneva when rated by MarketBeat users. Likewise, 74.74% of users gave Sarepta Therapeutics an outperform vote while only 66.67% of users gave Valneva an outperform vote.

Company	Underperform	Outperform
Sarepta Therapeutics	Outperform Votes 1488 74.74%	Underperform Votes 503 25.26%
Valneva	Outperform Votes 42 66.67%	Underperform Votes 21 33.33%

Which has more risk & volatility, SRPT or VALN?

Sarepta Therapeutics has a beta of 0.61, suggesting that its stock price is 39% less volatile than the S&P 500. Comparatively, Valneva has a beta of 1.81, suggesting that its stock price is 81% more volatile than the S&P 500.

Is SRPT or VALN more profitable?

Sarepta Therapeutics has a net margin of -11.12% compared to Valneva's net margin of -43.08%. Sarepta Therapeutics' return on equity of -14.88% beat Valneva's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Sarepta Therapeutics	-11.12%	-14.88%	-5.12%
Valneva	-43.08%	-43.05%	-16.23%

Do analysts rate SRPT or VALN?

Sarepta Therapeutics currently has a consensus target price of $74.13, indicating a potential upside of 243.83%. Valneva has a consensus target price of $15.50, indicating a potential upside of 163.61%. Given Sarepta Therapeutics' higher possible upside, research analysts clearly believe Sarepta Therapeutics is more favorable than Valneva.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Sarepta Therapeutics	1 Sell rating(s)	10 Hold rating(s)	12 Buy rating(s)	1 Strong Buy rating(s)	2.54
Valneva	0 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	3.00

Which has preferable earnings and valuation, SRPT or VALN?

Sarepta Therapeutics has higher revenue and earnings than Valneva. Sarepta Therapeutics is trading at a lower price-to-earnings ratio than Valneva, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Sarepta Therapeutics	$1.90B	1.11	$235.24M	-$2.69	-8.01
Valneva	$183.52M	2.73	-$13.25M	-$1.19	-4.94

Do institutionals & insiders believe in SRPT or VALN?

86.7% of Sarepta Therapeutics shares are held by institutional investors. Comparatively, 11.4% of Valneva shares are held by institutional investors. 7.7% of Sarepta Therapeutics shares are held by company insiders. Comparatively, 14.9% of Valneva shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Does the media favor SRPT or VALN?

In the previous week, Sarepta Therapeutics had 83 more articles in the media than Valneva. MarketBeat recorded 87 mentions for Sarepta Therapeutics and 4 mentions for Valneva. Valneva's average media sentiment score of 0.70 beat Sarepta Therapeutics' score of -0.35 indicating that Valneva is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Sarepta Therapeutics	7 Very Positive mention(s)	15 Positive mention(s)	23 Neutral mention(s)	21 Negative mention(s)	6 Very Negative mention(s)	Neutral
Valneva	2 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Sarepta Therapeutics beats Valneva on 12 of the 19 factors compared between the two stocks.